I
n February 2017, the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) published updated "Guidelines for the Management of Dyslipidemia and Prevention of Cardiovascular Disease" (1) . The update encompassed recent important clinical trial outcomes and additional research related to the treatment of dyslipidemia as identified by the 16-member AACE/ ACE writing committee. The update retains LDL cholesterol treatment goals, which are supported by clinical trials and have been useful to both clinicians and patients. However, for the first time, it extends an LDL cholesterol goal to <55 mg/dL for patients who are at "extreme risk."
The updated guidelines include 87 graded recommendations and 695 evidence-ranked references. Fifteen clinically related questions are addressed by the recommendations and supported by the evidence base ( Table 1 ). The complete AACE/ ACE guidelines, including both an executive summary and a comprehensive evidence base, are available from www.aace.com/files/lipid-guidelines. pdf. The remainder of this article summarizes key points from the guidelines.
Assessing Risk
The 10-year risk of a coronary event should be determined by assessment using one or more of the following tools: 1) the Framingham Risk Assessment Tool, 2) the Reynolds Risk Score, 3) the Multi-Ethnic Study of Atherosclerosis (MESA) 10-year ASCVD (atherosclerotic cardiovascular disease) Risk with Coronary Artery Calcification (CAC) Calculator, and 4) the UK Prospective Diabetes Study (UKPDS) Risk Engine for patients with type 2 diabetes (1) .
Although each of these tools can be used to predict 10-year risk, the MESA risk score is emerging as the preferred tool using traditional risk factors and CAC to predict 10-year coronary heart disease (CHD) risk. The incorporation of CAC into this risk score significantly improves risk prediction in patients with or without traditional risk factors and in patients with a family history of premature CHD. CAC is also the strongest predictor of cardiovascular disease (CVD) in low-risk patients (1) (2) (3) (4) .
Using a 10-year risk assessment tool is useful in patients with diabetes when clinical features do not clearly indicate high, very high, or extreme risk status (Table 2) . j e l l i n g e r
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Extreme Risk
A new "extreme risk" category is introduced for the first time as an ASCVD risk category for patients considered at risk beyond "very high risk" (1) [6] ) and large supporting meta-analyses such as the Cholesterol Treatment Trialists' Collaboration 2010 (7) , which revealed that further lowering of LDL cholesterol beyond prior recommendations produced better outcomes in individuals with CVD. IMPROVE-IT demonstrated lower rates of cardiovascular events, primarily in patients with diabetes and acute coronary syndrome (ACS), when LDL cholesterol levels were lowered to 53 mg/dL when combining ezetimibe with simvastatin compared to simvastatin alone, where an average LDL cholesterol of 69 mg/dL was achieved (5) . The FOURIER trial validated this category by demonstrating a no-threshold continuum of CVD event reduction by achieving an average LDL cholesterol of 30 mg/dL in patients treated with evolocumab and high-intensity statin compared to those treated with high-intensity statin alone. At 26 months, myocardial infarction (MI) was reduced by 27%, stroke by 21%, and coronary revascularization by 22% in the evolocumabtreated patients (6) . Patients with extreme risk, which includes patients with diabetes and clinical ASCVD, have an LDL cholesterol treatment goal of <55 mg/dL. Patients with diabetes may be at high, very high, or extreme risk (1) .
Patients with clinical ASCVD and stage 3 or 4 chronic kidney disease (CKD) or heterozygote familial hypercholesterolemia (HeFH) are at extreme risk (1) . Growing evidence suggests that individuals with CKD, who comprise a growing population, have increased risk for ASCVD (8) . It appears that the increased risk of ASCVD does not occur only in individuals with end-stage renal disease, but also in those with mild to moderate chronic renal dysfunction. These findings led the National Kidney Foundation to consider CKD as an ASCVD equivalent (9).
Familial hypercholesterolemia (FH) is caused by genetic mutations passed on by one parent (HeFH) or both parents (homozygous FH [HoFH]) (10) . HoFH prevalence ranges from 1 in 160,000 to 1 in 250,000. Individuals with HoFH have extremely high LDL cholesterol levels (>500 mg/dL) and premature cardiovascular risk. Many with HoFH experience their first coronary event in childhood or adolescence. HeFH prevalence ranges from 1 in 200 to 1 in 250 (11, 12) . Individuals with HeFH can present with LDL cholesterol levels of 90-500 mg/dL and have premature cardiovascular risk. On average, individuals with HeFH experience their first coronary event at the age of 42 years (~20 years younger than the general population). Early treatment is recommended for all individuals with FH, with a goal of reducing LDL cholesterol levels by 50% from baseline (13) ( Table 2) .
ASCVD Risk Categories and LDL Cholesterol Treatment Goals
LDL cholesterol treatment goals, which should be personalized according to levels of risk, and CVD risk categories are as follows (1) .
For individuals at low risk (i.e., with no risk factors), an LDL cholesterol goal <130 mg/dL (non-HDL cholesterol <160 mg/dL) is recommended.
For individuals at moderate risk (i.e., with two or fewer risk factors and a calculated 10-year risk <10%), an LDL cholesterol goal <100 mg/dL (non-HDL cholesterol [total cholesterol minus
For individuals at high risk (i.e., those with an ASCVD equivalent HDL cholesterol should be >40 mg/dL, but also as high as possible, primarily through the use of lifestyle interventions (e.g., weight loss, physical activity, and tobacco cessation) and, if risk factors are present (e.g., borderline elevated LDL cholesterol levels, a family history of premature ASCVD, or a personal history of ASCVD), also through the use of pharmacotherapy primarily focused on reducing LDL cholesterol (1) .
For most individuals, a non-HDL cholesterol goal 30 mg/dL higher than the individual's specific LDL cholesterol goal is recommended. For individuals at extreme risk, a non-HDL cholesterol goal 25 mg/dL higher than the individual-specific LDL cholesterol goal is recommended (1) .
For individuals at increased risk of ASCVD, including those with diabetes, an optimal apo B goal is <90 mg/dL, whereas for individuals with established ASCVD or diabetes plus one or more additional risk factor(s), an optimal apo B goal is <80 mg/dL, and for individuals at extreme risk, an optimal apo B goal is <70 mg/dL (1) .
A triglyceride goal <150 mg/dL is recommended. Lowering triglycerides when significantly elevated is important in reducing the risk for pancreatitis. Hypertriglyceridemia usually identifies insulin resistance, and evidence suggests that because hypertriglyceridemia is closely associated with highly atherogenic lipoprotein particles, it is an independent risk factor for ASCVD (1, 14) .
Screening for ASCVD Risk
Screening guidelines for dyslipidemia vary by age-group; however, the decision to screen should always be based on clinical judgment. Specific indications exist to alert health care providers to conduct screenings. j e l l i n g e r
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• Triglyceride levels also should be part of routine lipid screening. Moderate elevations (≥150 mg/dL) may identify individuals at risk for insulin resistance syndrome, and levels ≥200 mg/dL may identify individuals at substantially increased ASCVD risk (1) . Apo B and/or an apo B/apo A1 ratio calculation and evaluation may be useful in at-risk individuals (those with triglycerides ≥150 mg/dL, HDL cholesterol <40 mg/dL, prior ASCVD event, type 2 diabetes, and/or insulin resistance syndrome even when at target LDL cholesterol levels) to assess residual risk and guide decisionmaking. Apo B measurements (reflecting the particle concentration of LDL and all other atherogenic lipoproteins) can be useful to assess and affirm the success of LDL cholesterollowering therapy (1, 15, 16) .
Additional Screening Tests
CAC measurement has been shown to be of high predictive value and is useful in refining risk stratification to determine the need for more aggressive treatment strategies. CAC measurements are not necessary routinely in patients with diabetes because, in most instances, diabetes is considered a CVD equivalent and risk stratification is not required. However, in individual circumstances in which risk is unclear in a person with diabetes, assessing CAC can be useful. In the short term in people with diabetes, the absence of calcified plaque appears to have the same predictive value as in individuals without diabetes.
High-sensitivity C-reactive protein (hsCRP) can help stratify ASCVD risk in individuals with a standard risk assessment that is borderline and in those with an intermediate or higher risk with an LDL cholesterol concentration <130 mg/dL (1).
Lipoprotein-associated phospholipase A2, which in some studies has demonstrated more specificity than hsCRP, may be measured when necessary to further stratify ASCVD risk, especially when hsCRP is elevated (1).
Lipoprotein (a) assessment is not generally recommended because of wide variability in populations and a lack of standardization, although it may provide useful information to ascribe risk in Caucasians with ASCVD and in those with an unexplained family history of early ASCVD, as well as in those with unknown family history, such as adopted individuals (1) .
Because the benefits of routine measurement of homocysteine, plasminogen activator inhibitor-1, or other inflammatory markers have not been demonstrated, these assessments are not recommended (1) .
Carotid intima media thickness assessment may be considered in certain individuals to refine risk stratification and determine the need for more aggressive ASCVD preventive strategies (1) .
F R O M R E S E A R C H T O P R A C T I C E / R E C E N T D I A B E T E S G U I D E L I N E S
Diabetes as a Risk Factor
Type 2 Diabetes
Based on several epidemiological studies, individuals with type 2 diabetes should be considered to be at high, very high, or extreme risk for ASCVD (1) . Approximately 65% of diabetesrelated mortality is due to heart disease and cerebrovascular accident (CVA (20) . Although diabetes is a dominant CVD risk factor, the dyslipidemia associated with diabetes is characterized by elevated triglycerides, low HDL cholesterol, and normal, high-normal, or mildly elevated LDL cholesterol levels (1).
Type 1 Diabetes
Based on epidemiological and prospective cohort studies, individuals with type 1 diabetes, including late-onset diabetes (at >30 years of age) and duration >15 years or with two or more major CVD risk factors (e.g., albuminuria, stage 3 or 4 CKD, and initiation of intensive control >5 years after diagnosis), poorly controlled A1C, or insulin resistance with metabolic syndrome and an hsCRP >3.0 mg/dL should be considered to have a risk equivalent to that of people with type 2 diabetes (1).
Treatment Recommendations
A comprehensive strategy to control lipid levels and address associated metabolic abnormalities and modifiable risk factors is recommended, primarily using lifestyle changes and patient education, with pharmacotherapy as needed to achieve evidence-based targets (1).
Physical Activity
A reasonable and feasible approach to fitness therapy (i.e., exercise programs that include at least 30 minutes of moderate-intensity physical activity [consuming 4-7 kcal/min] four to six times weekly, with an expenditure of at least 200 kcal/day) is recommended. Suggested activities include brisk walking, riding a stationary bike, water aerobics, cleaning/scrubbing, mowing the lawn, and sporting activities (1).
Daily physical activity goals can be met in a single session or in multiple sessions throughout the course of a day (10-minute minimum per session). For some individuals, breaking activity up throughout the day may help improve adherence with physical activity programs. In addition to aerobic activity, muscle-strengthening activity is recommended at least 2 days per week (1).
Medical Nutrition Therapy
For adults, a reduced-calorie diet consisting of fruits and vegetables (combined five or more servings/day), grains (primarily whole grains), fish, and lean meats is recommended. For adults, the intake of saturated fats, trans fats, and cholesterol should be limited. LDL cholesterol-lowering macronutrient intake should include plant stanols/sterols (~2 g/day) and soluble fiber (10-25 g/day). Primary preventive nutrition consisting of healthy lifestyle habits is recommended in all healthy children (1).
Smoking Cessation
Smoking cessation should be strongly encouraged and facilitated.
Pharmacologic Therapy
In individuals at risk for ASCVD, aggressive pharmacological lipidmodifying therapy is recommended to achieve appropriate LDL cholesterol goals (Table 3 ) (1).
Statins
Therapy with statins (also called HMG-CoA [hydroxymethylglutarylcoenzyme A] reductase inhibitors) is recommended as the primary pharmacological agent to achieve target LDL cholesterol goals on the basis of morbidity and mortality outcome trials (1, (21) (22) (23) (24) (25) (26) (27) . For clinical decisionmaking, mild elevations in blood glucose levels and/or an increased risk of new-onset type 2 diabetes associated with intensive statin therapy do not outweigh the benefits of statin therapy for ASCVD risk reduction.
In individuals with high or very high risk, further lowering of LDL cholesterol beyond established targets with statins results in additional ASCVD event reduction and may be considered. Very-high-risk individuals with established coronary, carotid, and peripheral vascular disease or diabetes who also have one or more additional risk factors should be treated with statins to target a reduced LDL cholesterol treatment goal of <70 mg/dL. Individuals at extreme risk should be treated with statins to target an even lower LDL cholesterol treatment goal of <55 mg/ dL.
The statin dose in all patients, including those with diabetes, is determined by the dose necessary to achieve the appropriate LDL goal alone or in combination with other LDL cholesterol-lowering therapy. Statin intolerance, primarily consisting of myalgias, is a clinical problem of uncertain frequency requiring lowering the statin dose, switching statins, or in some instances avoiding statins entirely (1).
Fibrates
Fibrates should be used to treat severe hypertriglyceridemia (triglycerides >500 mg/dL) (1). Based on sub- • When co-administered with statins or fenofibrate, risks associated with those drugs remain (e.g., myopathy/ rhabdomyolysis and cholelithiasis) • The most common adverse reactions with similar rates for drug versus placebo were for: • Causes increases in hepatic fat (steatosis) with or without concomitant elevated transaminases, which may be a risk for progressive liver diseases
• Also causes steatosis of the small intestine with resulting abdominal pain and steatorrhea unless a very-low-fat diet is followed; may also cause fat-soluble vitamin deficiency unless vitamin supplements are taken
• Caution should be exercised when used with other drugs with potential hepatoxicity; because of hepatoxicity risk, only available through REMS program
Antisense apo B oligonucleotide (mipomersen subcutaneous injection)
• ↓ LDL-C 21%, TC 19%, apo B 24%, and non-HDL-C 22% in individuals with HoFH by degrading mRNA for apo B-100, the principal apolipoprotein needed for hepatic synthesis of VLDL (and subsequent intra-plasma production of IDL and LDL) • Can cause increases in transaminases (ALT, AST); monitoring of ALT, AST, alkaline phosphatase, and total bilirubin before initiation and of ALT and AST during treatment is recommended
• Causes increases in hepatic fat (steatosis) with or without concomitant elevated transaminases, which may be a risk for progressive liver diseases
• Caution should be exercised when used with other drugs with potential hepatoxicity; because of hepatoxicity risk, only available through REMS program • ↓ TG 27-45%, TC 7-10%, VLDL-C 20-42%, apo B 4%, and non-HDL-C 8-14% in individuals with severe hypertriglyceridemia most likely by reducing hepatic VLDL-TG synthesis and/or secretion and enhancing TG clearance from circulating VLDL particles; other potential mechanisms of action include increased ß-oxidation, inhibition of acyl-CoA, 1,2-diacylglyceral acyltransferase, decreased hepatic lipogenesis, and increased plasma lipoprotein activity
• Icosapent ethyl ↓ LDL-C 5%, whereas,omega-3-acid ethyl esters ↑ LDL-C 45% • TG levels should be carefully assessed before initiating therapy and periodically during therapy
• Omega-3-acid ethyl esters can increase LDL-C levels; monitoring LDL-C levels during treatment is recommended
• May prolong bleeding time; periodic monitoring of coagulation status should be undertaken in patients receiving treatment with omega-3 fatty acids and other drugs affecting coagulation
• Periodic monitoring of ALT and AST levels during treatment is recommended for patients with hepatic impairment; some patients may experience increases in ALT levels only
• Caution should be exercised when treating patients with a known hypersensitivity to fish and/or shellfish
• In patients with severe hypertriglyceridemia, the effect of omega-3 fatty acids on cardiovascular morbidity and mortality and the risk of pancreatitis has not been determined in patients with severe hypertriglyceridemia
• In patients with paroxysmal or persistent AF, therapy with omega-3-acid ethyl esters may be associated with increased frequency of symptomatic AF or flutter, especially within the first 2-3 months after initiation
• The most common adverse events in patients receiving omega-3 fatty acids included arthralgia (2.3%), eructation (4%), dyspepsia (3%), and taste perversion (4%); patients may also experience constipation, gastrointestinal disorders, vomiting, rash, or pruritus
• Omega-3 fatty acids should be used with caution in nursing mothers and should only be used in pregnant women if the benefits of treatment outweigh the potential risk of fetal harm 
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Omega-3 Fish Oil
Prescription omega-3 fish oil 2-4 g daily should be used to treat severe hypertriglyceridemia (triglycerides >500 mg/dL). Dietary supplements are not approved by the U.S. Food and Drug Administration (FDA) for treatment of hypertriglyceridemia and generally are not recommended for this purpose (1).
Niacin
Niacin therapy is recommended principally as an adjunct for reducing triglycerides. Niacin should not be used in individuals aggressively treated with a statin because of the absence of additional benefit in patients with well-controlled LDL cholesterol (1).
Bile Acid Sequestrants
Bile acid sequestrants may be considered for reducing LDL cholesterol and apo B and modestly increasing HDL cholesterol but may increase triglycerides (1).
Cholesterol Absorption Inhibitors
Ezetimibe may be considered as monotherapy in reducing LDL cholesterol and apo B, especially in statinintolerant individuals. Ezetimibe can be used in combination with statins to further reduce both LDL cholesterol and ASCVD risk (1). 
Combination Therapy
Combination therapy with lipidlowering agents should be considered when the LDL cholesterol/non-HDL cholesterol level is markedly increased and monotherapy (usually with a statin) does not achieve the therapeutic goal (1). An acceptable LDL cholesterol level in children and adolescents is <100 mg/dL, although some pediatric guidelines consider <110 mg/dL acceptable. A level 100-129 mg/dL is considered borderline, and a level >130 mg/dL is considered high (1). (1, 14, 33) • Reassess individuals' lipid status 6 weeks after therapy initiation and again at 6-week intervals until the treatment goal is achieved.
Follow-Up and Monitoring
• While on stable lipid therapy, individuals should be tested at 6-to 12-month intervals.
• While on stable lipid therapy, the specific interval of testing should depend on individual adherence to therapy and lipid profile consistency; if adherence is a concern or the lipid profile is unstable, the individual will probably benefit from more frequent assessment.
• More frequent lipid status evaluation is recommended in situations such as deterioration of diabetes control, use of a new drug known to affect lipid levels, progression of atherothrombotic disease, considerable weight gain, unexpected adverse change in any lipid parameter, development of a new ASCVD risk factor, or convincing new clinical trial evidence or guidelines that suggest stricter lipid goals.
• Liver transaminase levels should be measured before and 3 months after initiating niacin or fibric acid treatment because most liver abnormalities occur within 3 months of treatment initiation. Liver transaminase levels should be measured periodically (e.g., semiannually or annually) thereafter.
• Creatine kinase levels should be assessed and the statin discontinued, at least temporarily, when individuals report clinically significant myalgias or muscle weakness while on statin therapy.
Cost-Effectiveness
Non-pharmacological interventions such as dietary management and smoking cessation are the most cost-effective options available for ASCVD prevention. When non-pharmacological interventions fail, pharmacological intervention is a cost-effective option for primary and secondary intervention among individuals at moderate to high risk. Among otherwise healthy individuals at low risk, the cost-effectiveness of primary pharmacological intervention varies on the basis of age and sex (1) .
Statins have proven to be costeffective in both primary and secondary prevention of ASCVD events in individuals at moderate to high risk or in individuals with an LDL cholesterol ≥190 mg/dL (14,34,35). Fibrates are cost-effective as monotherapy and in combination therapy for lowering triglycerides and raising HDL cholesterol and reducing CVD events in individuals with triglycerides >200 mg/dL and HDL cholesterol <40 mg/dL (36,37). The cost-effectiveness for ezetimibe is unclear (38, 39) , but with recent clinical trial outcome data and price reductions, ezetimibe may emerge as a cost-effective strategy to achieve LDL cholesterol goals and reduce CVD events. Assessment of the cost-effectiveness of PCSK9 inhibitors awaits further clinical trial data on already-demonstrated CVD event reduction and a longer analysis to determine a CVD death benefit. 
